Diagonal Bio AB (9F1) Stock Statistics & Valuation Metrics

Diagonal Bio AB has a market cap or net worth of €983.99K. The enterprise value is -€3.14M.

Diagonal Bio AB has 1,214,965,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

Diagonal Bio AB’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -54.43%.

The current PE Ratio of Diagonal Bio AB is -1.03. Diagonal Bio AB’s PEG ratio is 0.00.

In the last 12 months, Diagonal Bio AB had revenue of 23.00K and earned -11.68M in profits. Earnings per share was -0.32.

In the last 12 months, operating cash flow was -12.90M and capital expenditures -4.62M, giving a free cash flow of -17.53M billion.

Diagonal Bio AB pays an annual dividend of ―, resulting in a dividend yield of ―

Diagonal Bio AB upcoming earnings date is Aug 22, 2025, Before Open (Not Confirmed).

Diagonal Bio AB as a current ratio of 0.65, with Debt / Equity ratio of 0.00%

In the past 12 months, Diagonal Bio AB has paid 0.00 in taxes.

Diagonal Bio AB EV to EBITDA ratio is -0.79, with an EV/FCF ratio of -0.95.

Diagonal Bio AB has €1.73M in cash and marketable securities with kr0.00 in debt, giving a net cash position of -€1.73M billion.

Gross margin is 1011.82%, with operating margin of -50286.96%, and net profit margin of -50773.91%.

The average price target for Diagonal Bio AB is ―, which is 11.43% higher than the current price. The consensus rating is ―